LINK TO ONE OF OUR 52 MEMBER COUNTRIES FOR LOCAL SUPPORT, ADVICE AND NEWS
view map
close- Finland
- Norway
- Sweden
- Estonia
- Russian Federation
- Latvia
- Denmark
- Lithuania
- United Kingdom
- Netherlands
- Ireland
- Poland
- Germany
- Belgium
- Czech Republic
- Ukraine
- Slovakia
- Luxembourg
- Moldova, Republic of
- Austria
- France
- Switzerland
- Romania
- Slovenia
- Croatia
- Serbia
- Bosnia & Herzegovina
- Bulgaria
- Italy
- Macedonia, the Former Yugoslav Republic of
- Spain
- Greece
- Israel
News
Launch of the 'Spotlight on Gaucher Film Contest'
15 July 2015
'Spotlight on Gaucher Film Contest'
has been launched by Shire to encourage those touched by Gaucher disease to share a short video about their experience with the condition. Shire want you to share your own personal story of living with …UK Gauchers Association Granted a Positive Opinion For Orphan Designation For Gene Therapy For Gaucher Disease
27 February 2015
UK Gauchers Association Granted a Positive Opinion For Orphan Designation For Gene Therapy For Gaucher Disease
27 February 2015
The UK Gauchers Association is delighted to announce that on 12 February 2015 the Committee for Orphan Medicinal Products …Watch the Official Rare Disease Day 2015 Video!
17 February 2015
Watch and Share the Official Rare Disease Day 2015 Video!
Bring People Living with a Rare Disease out of the Shadows and into the Spotlight
European Commission Grants Marketing Authorization for Cerdelga (eliglustat), Genzyme`s oral therapy for Gaucher Disease Type 1
23 January 2015
Paris - January 22, 2015 - Sanofi and its subsidiary Genzyme announced today that the European Commission (EC) has granted marketing authorization for Cerdelga® (eliglustat) capsules, a first line oral therapy for certain adults living with …European CHMP Adopts Positive Opinion for Genzyme's Cerdelga (eliglustat) Capsules
23 November 2014
21.November 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval …Genzyme Announces Launch of `Expression of Hope III` Program to Build Awareness of Lysosomal Storage Disorders Through Works of Art
16 September 2014
Genzyme Announces Launch of “Expression of Hope III” Program to Build Awareness of Lysosomal Storage Disorders Through Works of Art
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today …
FDA Approval of Pediatric Indication for ELELYSO (taliglucerase alfa)
28 August 2014
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease
Pfizer Inc. (NYSE:PFE) and Protalix …
FDA Approves Genzyme's Cerdelga (eliglustat) Capsules
20 August 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only first-line oral therapy for …
Joint proposal to facilitate clinical investigation of new medicines for Gaucher disease in children
17 May 2014
14/05/2014
European Medicines Agency and US Food and Drug Administration release joint proposal to facilitate clinical investigation of new medicines for Gaucher disease in children
The European Medicines Agency (EMA) and the United States Food …
FDA Grants Priority Review for Cerdelga (Eliglustat)
16 December 2013
FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company announced today that the Food and Drug Administration …
